drugset / Trial / NCT04017845

Screening for Colorectal Cancer in Average and High Risk Population

NCT04017845

Non-randomizedParallel-groupOpen-labelScreening

Summary

The existing evidence from epidemiological studies and randomized controlled trials has consistently assures the cost effectiveness and the influential role of screening in reducing incidence rates and deaths caused by Colorectal Cancer (CRC). Population based organized screening programmes, which should be considered an obligation that is not to be postponed, require valuable information that can be reliably extrapolated from well-designed pilot study conducted prior to programme implementation. The main objectives of the current pilot CRC screening project, named after "Al-Kindy College of Medicine", was to evaluate and explore the specific aspects of the intended population-based organized CRC screening programme, including: barriers affecting adherence to the programme, performance indicators of the proposed screening programme, the target population in which CRC screening is a legitimate healthcare priority, quality assurance of screening tests and colonoscopy services, and to propose an algorithm that will provide a clinically and logistically acceptable positivity rate.

Timeline

Start
2015-04-01
Primary completion
2017-05-30
Completion
2017-10-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diltiazem Small molecule 2 % Rectal
Comparator Lidocaine Other / unclassified 40 mg Rectal
Comparator Nitroglycerin Unknown Rectal
Comparator Tribenoside Small molecule 400 mg Rectal